0.637
0.06 (10.11%)
| Previous Close | 0.579 |
| Open | 0.600 |
| Volume | 1,525,832 |
| Avg. Volume (3M) | 1,182,090 |
| Market Cap | 1,994,977,664 |
| Price / Sales | 217.34 |
| Price / Book | 97.15 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 |
| Operating Margin (TTM) | -17,994.78% |
| Diluted EPS (TTM) | -0.590 |
| Total Debt/Equity (MRQ) | 0.91% |
| Current Ratio (MRQ) | 10.96 |
| Operating Cash Flow (TTM) | -121.30 M |
| Levered Free Cash Flow (TTM) | -114.20 M |
| Return on Assets (TTM) | -28.29% |
| Return on Equity (TTM) | -45.28% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | ProKidney Corp. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -2.5 |
| Average | -1.00 |
|
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 30.05% |
| % Held by Institutions | 41.66% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Brown University | 31 Mar 2025 | 1,000,000 |
| 52 Weeks Range | ||
| Median | 1.00 (56.94%) | |
| Total | 1 Sell | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 30 Jun 2025 | 1.00 (56.94%) | Sell | 0.592 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 Jul 2025 | Announcement | ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware |
| 12 May 2025 | Announcement | ProKidney Reports First Quarter 2025 Financial Results and Business Highlights |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |